Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy

Pharmacotherapy

Volumn 35, Issue 6, 2015, Pages 600-607

  Awissi, Don Kelena ^a   Beauchamp, Annie ^a   Hébert, Elisabeth ^a   Lavigne, Viviane ^a   Munoz, Danya Lucia ^a   Lebrun, Geneviève ^a   Savoie, Michel ^a   Fagnan, Mylène ^a   Amyot, Julie ^a   Tétreault, Nicolas ^a   Robitaille, Robert ^a   Varin, France ^b   Lavallée, Christian ^a   Pichette, Vincent ^a   Leblanc, Martine ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

continuous renal replacement therapy; critical care; hemodiafiltration; pharmacokinetics; piperacillin tazobactam; prolonged infusion

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; CANADA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; END STAGE RENAL DISEASE; FEMALE; HUMAN; INFECTION; INTENSIVE CARE; KIDNEY CLEARANCE; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PHARMACODYNAMICS; PROSPECTIVE STUDY; SEIZURE; UNBOUND FRACTION; ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; DRUG EFFECTS; HEMODIAFILTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TERTIARY CARE CENTER;

AGED; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TERTIARY CARE CENTERS;

EID: 84931826621     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1604     Document Type: Conference Paper

References (28)

1. Lagace-Wiens PR, Decorby MR, Baudry PJ, et al., Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables. Can J Infect Dis Med Microbiol 2008; 19: 282-6.
2. Scaglione F, Paraboni L,. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents 2008; 32: 294-301.
3. Turnidge JD,. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27: 10-22.
4. Drusano GL,. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
5. Craig WA,. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
6. Kim A, Sutherland CA, Kuti JL, Nicolau DP,. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 2007; 27: 1490-7.
7. Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB,. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 2009; 43: 1747-54.
8. Mah GT, Mabasa VH, Chow I, Ensom MHH,. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. Ann Pharmacother 2012; 46: 265-75.
9. Lodise TP Jr, Lomaestro B, Drusano GL,. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
10. Yost RJ, Cappelletty DM, RECEIPT study group. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 2011; 31: 767-75.
11. Bellomo R, Ronco C,. Continuous haemofiltration in the intensive care unit. Crit Care 2000; 4: 339-45.
12. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M, Alberta Kidney Disease Network. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008; 299: 793-805.
13. Bauer SR, Salem C, Connor MJ Jr, et al., Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol 2012; 7: 452-7.
14. Seyler L, Cotton F, Taccone FS, et al., Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15: R137.
15. Roberts DM, Roberts JA, Roberts MS, et al., Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40: 1523-8.
16. Zhanel GG, Adam HJ, Low DE, et al., Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69: 291-306.
17. Mueller SC, Majcher-Peszynska J, Hickstein H, et al., Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002; 46: 1557-60.
18. Lister PD, Prevan AM, Sanders CC,. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob Agents Chemother 1997; 41: 721-7.
19. Arzuaga A, Isla A, Gascon AR, et al., Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC. Biomed Chromatogr 2005; 19: 570-8.
20. CLSI. Performance standards for antimicrobial susceptibility testing; 23th informational supplement; CLSI document M100-S23. Wayne, PA: CLSI.
21. Arzuaga A, Maynar J, Gascon AR, et al., Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005; 45: 168-76.
22. Asin-Prieto E, Rodriguez-Gascon A, Troconiz IF, et al., Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J Antimicrob Chemother 2014; 69: 180-9.
23. Cheatham SC, Fleming MR, Healy DP, et al., Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013; 41: 52-6.
24. World Health Organisation. Obesity and overweight fact sheet N8311. Available from http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed November 19, 2013.
25. Pfizer 2012. Piperacillin sodium and tazobactam sodium (Zosyn) product information. New York, NY: Pfizer. Available from http://labeling.pfizer.com/showlabeling.aspx?id=416. Accessed November 19, 2013.
26. Wong G, Briscoe S, Adnan S, et al., Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 2013; 57: 6165-70.
27. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ,. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001; 48: 881-5.
28. van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA,. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997; 23: 873-7.